LEXX Lexaria Bioscience Corp.

CIK 0001348362 50 ready 8-Ks latest February 6, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing February 6, 2026, 6:59 PM ET

Top materiality 0.75

Event mix other_material ×35 · leadership ×7 · regulatory ×5

Sentiment 13 pos · 4 neg · 33 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for LEXX

Highest-materiality recent filing

Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37

September 29, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×2

Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
Warrants for 2,666,667 shares at $1.37, immediately exercisable, 5-year term from resale registration.

Read filing →

February 6, 2026, 6:59 PM ET other material materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure

Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
September 29, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×2

Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37

Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
December 18, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.0

Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial

Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
October 2, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×3

Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024

Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.
September 5, 2024, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman

Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.
July 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns

CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
April 30, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike

Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.
March 15, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024

Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.
March 1, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01

Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1

FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.
February 16, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements ×2

Lexaria raises $3.6M in registered direct offering and private placement

Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.
January 30, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 8.01

Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD

Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.
January 24, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent

Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.
January 4, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Lexaria's DehydraTECH semaglutide outperforms Rybelsus in human pilot study

DehydraTECH semaglutide showed 43% higher peak blood levels vs Rybelsus; levels higher at all 19 time points.
October 18, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Lexaria receives Nasdaq bid price deficiency notice; 180-day cure until April 15, 2024

Received Nasdaq notice on Oct 17, 2023 for failing to maintain $1.00 minimum bid price for continued listing on Nasdaq Capital Market.
October 12, 2023, 7:59 PM ET other material materiality 0.60 neutral item 5.07 item 8.01 item 9.01 ◈ Shareholder Votes

Lexaria shareholders approve reverse stock split; company granted two Canadian patents

Shareholders approved reverse stock split with ratio between 2:1 and 12:1 (67% for).
October 3, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

Lexaria raises $1.57M in registered direct offering and private placement

Gross proceeds of $1.57M from sale of 889,272 shares at $0.97, pre-funded warrants for 729,058 shares at $0.9699, and private placement warrants for 1,618,330 shares at $0.97.
July 20, 2023, 7:59 PM ET other material materiality 0.60 positive item 8.01

Lexaria granted three US patents for DehydraTECH in hypertension and nicotine delivery

Issued US Patents #11,666,543 and #11,666,544 for DehydraTECH in treating hypertension.
June 23, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Lexaria receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Nasdaq letter dated June 22, 2023 cites LEXX not meeting $1.00 bid price requirement.
March 3, 2023, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Lexaria's DehydraTECH-CBD diabetes study shows weight loss, improved triglycerides and cholesterol in obese rats

7% body weight loss maintained over 8 weeks in obese diabetic Zucker rats dosed with DehydraTECH-CBD.
January 23, 2023, 6:59 PM ET leadership materiality 0.65 positive item 7.01

Lexaria Bioscience hires former GW Pharma USA President Julian Gangolli as Strategic Advisor

Julian Gangolli, former President of GW Pharmaceuticals USA, appointed as Strategic Advisor.
January 17, 2023, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 9.01

Lexaria CEO letter details FDA pre-IND success, new Japan client, no 2022 equity raise

FDA pre-IND meeting cleared path toward formal IND filing for DehydraTECH-CBD hypertension program; Phase 1(b) study expected in 2023.
November 30, 2022, 6:59 PM ET other material materiality 0.60 positive item 8.01

Lexaria Bioscience: DehydraTECH-CBD shows better seizure control at lower doses vs. Epidiolex in animal study

Pilot study: at 50 mg/kg, only DehydraTECH-CBD showed seizure reduction; at 75 mg/kg, full elimination in 66.6% of animals vs. 50% for Epidiolex.
October 28, 2022, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study

Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.
August 15, 2022, 7:59 PM ET regulatory materiality 0.75 positive item 8.01

Lexaria receives positive FDA pre-IND response for DehydraTECH-CBD hypertension program

FDA agreed to 505(b)(2) NDA pathway, typically enabling faster commercial approval.
June 9, 2022, 7:59 PM ET other material materiality 0.60 neutral item 8.01

Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension

Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.